Glycocyamine betaine as an adjunct in the treatment of neuromuscular disease patients
Aldes, J.H.
Journal of the Arkansas Medical Society 54(5): 186-194
1957
ISSN/ISBN: 0004-1858 PMID: 13475190 Document Number: 9050
1. A control study was made on the use of glycocyamine and ßine (ßsyamine) pluS rehabilitation on a group of 226 neuromuscular patients - multiple sclerosis category - over a period of five years. 2. The studies revealed that when the drug, glycocyamine and ßine (ßsyamine) was given in adequate doses and over a sufficient period of time, together with a rehabilitation program, the patients showed symptomatic relief, functional improvement, increased strength and muscle tone, and a sense of well-being. 3. In this group of 226 patients, biochemical analyses were made on 113 samples of quadriceps muscle. 4. The clinical findings as well as the biochemical analyses have demonstrated that the individuals on glycocyamine and ßine (ßsyamine) plus a rehabilitation program showed marked improvement clinically and maintained the control levels of creatine phosphate and ADP plus ATP in their muscles after four to twelve months on this regime. 5. The patients on the rehabilitation program plus a placebo showed a decline in their general condition and a decrease in the levels of creative phosphate and ADP plus ATP in their muscles, which shows that these patients cannot support the additional exercise in the rehabilitation program without a decrease in the high energy phosphate compounds of the muscles. 6. The patients on the drug alone or on the placebo without a rehabilitation program showed no change. 7, This control study reveals that the administration of glycocyamine and ßine (ßsyamine) prevents a decrease in the levels of ATP and creatine phosphate of muscle during rehabilitation therapy, thereby maintaining the integrity of the tissue. 8. Glycocyamine and ßine (ßsyamine) does not affect a "cure" for multiple sclerosis but has proven to be valuable adjunctive therapy in the rehabilitation of the multiple sclerosis patient.
Document emailed within 1 workday
